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Abstract
Vaccination offers the most cost-effective approach to limiting the adverse impact 
of infectious and neoplastic diseases that reduce the quality of life in sub-Saha-
ran Africa (SSA). However, it is unclear what vaccine vectors would be most read-
ily implementable in the setting and at what age they should be applied for maxi-
mal efficacy. Adenoviruses (Ad) and Ad-based vectors have been demonstrated to 
induce effective humoral and cellular immune responses in animal models and in 
humans. However, because immunity associated with Ad infection is lifelong, there 
exists a debate as to whether pre-existing immunity might decrease the efficacy of 
Ad vectored vaccines. In order to begin to rationally develop vaccination strategies 
for SSA, we have quantified neutralizing antibodies (nAb) against Ad4, Ad5, Ad7, 
Ad26, Ad28, Ad45 and Ad48 in 67 adult women and their infants. We are the first 
to define the decay kinetics of transferred maternal nAb in infants as well as the 
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apparent initiation of de novo Ad responses. Our findings demonstrate that in Zam-
bian adults, robust nAb responses exist against each of the Ads tested and are effi-
ciently transferred to newborns. With few exceptions, neither the HIV-1 infection 
status of the mothers or the antiretroviral therapy (ART) treatment of HIV-1 dis-
ease had significant impact on maternal Ad nAb responses or their transfer to in-
fants. However, maternal Ad nAb decays in infants to a nadir at 12 months of age 
such that any of the seven Ad types could function as vaccine vectors. The defini-
tion of this ‘window of opportunity’ provides important foundational data for ra-
tional design and implementation of Ad vectors in this setting. 
Keywords: Adenovirus, Seroprevalence, Vector, Sub-Saharan Africa, HIV 
1. Introduction 
Sub-Saharan Africa (SSA) is disproportionately affected by infec-
tious diseases. The World Health Organization (WHO) has reported 
that two thirds of people living with HIV are in SSA [1]. Similarly, 
there is increased prevalence of tuberculosis, malaria, and other com-
municable diseases, as well as higher incidence of infection-related 
cancers. The incidence of infectious disease associates with signif-
icantly higher mortality in comparison to developed regions [2–4]. 
The public health impact of infectious diseases in SSA highlights the 
need for a more rational appreciation of vaccine designs with poten-
tial to reduce the regional disease burden. One important issue with 
vaccine design is the selection of suitable vector for the delivery of the 
vaccine, especially for infants in SSA, where effective childhood vac-
cinations could decrease disease incidence. 
One promising investigational vaccine platform is Adenovirus (Ad). 
Adenoviruses are large double stranded DNA viruses that, through de-
letion of genetic content and propagation to high titers, can be used 
as gene-delivery tools or vaccine vectors [5]. Historically, Ad vac-
cines and vectors were replication competent and thus had some risk 
of causing an Adenoviral infection [6,7]. Modern Ad constructs are 
typically replication incompetent or produce single cycle infections 
where no new Ad particles are produced but an inserted transgene 
of interest is efficiently expressed [8]. These recombinant Ads have 
been used developmentally as vectors in many Phase 1 and 2 vaccine 
safety trials against a diverse cadre of pathogens, including Zika vi-
rus, HIV, influenza, and Ebola; however, safety and efficacy have only 
Privatt  et  al .  in  Vacc ine  37  (2019)     3
been demonstrated for nonrecombinant vaccines used by the US mil-
itary against Ad types 4 and 7 [9–16]. Adenoviral vaccination typically 
produces a strong adaptive, Ad serotype-specific immune response 
[12,17]. The prevalence of pre-vaccination adenovirus-specific immu-
nity needs to be considered when predicting potential efficacy for vac-
cination in infants and young children. For example, Adenovirus type 
5 (Ad5) is commonly used in pre-clinical research and has been tested 
in human vaccine trials. Unfortunately, Ad5 has high worldwide se-
roprevalence suggesting that gene-delivery strategies based on that 
subtype could suffer from decreased effectiveness due to pre-exist-
ing neutralizing antibody (nAb) responses to the vector [18,19]. Con-
sistent with this concept, the HIV-1 STEP trial, which utilized an Ad5 
backbone to deliver the genes for HIV-1 gag, pol, and nef proteins as 
potential immunogens, was prematurely discontinued when a cor-
relation was observed between pre-existing Ad5 immunity and new 
HIV-1 infections [20]. However, data from non- HIV targeted Ad vac-
cine efforts, as well as studies using other viral vector systems, such 
as measles or dengue, have demonstrated preclinical and clinical effi-
cacy in the face of pre-existing neutralizing responses [21–24]. Thus, 
the impact of pre-existing Ad nAb on increased infection may be a 
unique function of HIV biology since it has not been consistently re-
ported by other groups utilizing various vaccine targets delivered by 
Ad vectors [24]. 
There are currently more than 60 serotypes of circulating Ads, sep-
arated into 7 subspecies, A-G, with varying geographical prevalence 
[25]. Adenoviruses are categorized based on infection associated con-
ditions, serology, propensity to cause tumors in rodents, and genome 
sequence. Here, we focus on the humoral immune responses to Ads 
from subgroups B–E. Adenovirus type D is the largest of the subspe-
cies and most newly discovered Ads fit into this category, yet most 
research has been performed on types B, C, and E [26,27]. Subspe-
cies B, C, and E adenoviruses are typically associated with acute re-
spiratory infections and conjunctivitis which can cause serious dis-
ease in immunocompromised individuals [28,29]. However, very little 
is known about the adenoviral serotypes that are commonly found in 
Africa, and a better understanding of the existing immune response 
against adenovirus is important for the designing of vaccine which can 
be used in the setting. We have included four different type D viruses, 
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Ad26, Ad28, Ad45 and Ad48, to expand on the limited knowledge of 
this subgroup. These adenovirus subspecies typically associate with 
respiratory diseases and conjunctivitis in humans and are likely re-
sponsible for many of the respiratory infections found in Africa and 
elsewhere [28,30]. 
In the current study, we characterized the humoral immune re-
sponse against seven different adenovirus serotypes in two Zambian 
cohorts consisting of mother-infant pairs collected at different time 
points. Many of the mothers were also HIV-1 infected. Investigation 
of immune responses in these cohorts will not only provide important 
information on the circulating adenoviral serotypes and the humoral 
immune response against adenovirus in the Zambian population, but 
also provide a better understanding of the pre-existing mother to in-
fant transmission of antiadenovirus antibodies, and the impact of un-
treated and treated HIV-1 infection on immune responses to adenoviral 
infections. Moreover, with the longitudinal infant follow-up speci-
mens, we investigated the decay kinetics of maternal neutralizing anti-
bodies (nAb) in infants and characterized the nadir of Ad seroreactiv-
ity prior to de novo response in those same infants. This information 
could form the foundation for rational selection of adenoviral gene de-
livery platforms for prophylactic or therapeutic application. 
Our results suggest that in Zambian adults, pre-existing humoral 
immunity exists against all 7 Ads tested and is efficiently transferred 
to newborns. However, due to maternal Ab decay in infants, any of 
the 7 Ad types could function as vaccine vectors between 12 and 24 
months of age, thereby defining the ‘window of opportunity’ for use 
of Ad vectors for vaccination of children in this setting. 
2. Materials and methods 
2.1. Cohort description and sampling 
There were two cohorts that were analyzed. The first cohort sam-
ples were collected between 1998 and 2003 in the pre-ART era as part 
of a prospective study investigating the effects of HIV-1 and KSHV in-
fection among Zambian mothers and their infants at the University 
Teaching Hospital and the University of Zambia School of Medicine, 
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Lusaka, Zambia. Written informed consent was obtained from all par-
ticipants. Blood samples were collected by venipuncture and blood was 
collected in acid citrate dextrose tubes and processed within 6 h of 
being drawn. Samples were frozen at −80 °C and shipped to the Uni-
versity of Nebraska- Lincoln for long-term storage. Protocols were re-
viewed and approved by the Institutional Review Boards at the Uni-
versity Teaching Hospital and the University of Nebraska-Lincoln. 
The second cohort samples were collected between 2010 and 2013 
when ART had become available in Zambia, and they were collected as 
part of an observational study investigating the effect of ART on KSHV 
transmission. Women with infants under the age of 12 months were 
enrolled into this study to examine the determinants of KSHV serocon-
version. This study was approved by the Institutional Review Board of 
the University of Nebraska-Lincoln and the University of Zambia Bio-
medical Research Ethics Committee. From these cohorts, a subset of 
63 mother-infant pairs (MIPs) were selected based on either mother 
HIV-1 infection status or ART treatment status. MIPs were also se-
lected based on infant follow-up sample availability for nAb testing. 
2.2. Recombinant adenovirus construction 
All Ad constructs contain a green fluorescent protein-luciferase 
(GFP-Luc) fusion gene under a CMV promoter within either the E3 
gene or between E1A and E1B. The recombinant Adenovirus types 4 
and 7 contain a GFPLuc reporter expression cassette in the E3 gene 
and were constructed as described in Weaver, 2014 [31]. Recombi-
nant Adenovirus types 26, 28, and 48 construction was described in 
Weaver and Barry [9]. Recombinant adenovirus type 45 was produced 
as previously described [31]. The recombinant Ad5-855 virus was con-
structed as described in [PMID: 10846098]. 
2.3. Recombinant adenovirus purification 
The recombinant adenovirus genomes containing the GFP-Luc in-
sert were linearized and buffer exchanged using a Strataprep PCR 
purification kit (Agilent Technologies). The linearized recombinant 
gDNA was transfected into HEK293T cells using the PolyFect Trans-
fection Reagent (Qiagen). Virus infection was indicated via plaque 
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formation, at which time cells were harvested and infectious prog-
eny virus was released by 3 freeze-thaw cycles. The recombinant Ad 
was amplified by sequential passages in HEK293T cells prior to final 
amplification in a Corning 10-cell stack (~6300 cm2). Amplified virus 
was purified by two sequential CsCl ultracentrifuge gradients and de-
salted using Econo-Pac 10DG desalting columns (Bio-Rad). The virus 
particle quantity was determined by absorption at 260 nm on a Nano-
Drop Lite Spectrophotometer (Thermo Fisher). Virus aliquots were 
stored at −80 °C in Ad-tris buffer (20 mM Tris-HCl, 100 mM NaCl2, 
1 mM MgCl26H2O, 10% glycerol). HEK293T cells were grown in Dul-
becco’s modified Eagle’s medium supplemented with 10% heat inac-
tivated FBS and 1% penicillin-streptomycin at 37 °C and 5% supple-
mented CO2. 
2.4. Adenovirus neutralization assay 
Adenovirus-specific nAb activity was quantified by a reduction in 
luciferase activity. Briefly, maternal or infant sera were heat inacti-
vated at 56°C for 60 min. Next, 20 µL of serum was added to 380 mL 
of DMEM containing 1.2 × 109 viral particles for a final volume of 400 
mL, resulting in a final serum dilution of 1:20. The serum/virus mix-
ture was incubated at 37 °C for 60 min. 100 µL was then added to 50 
mL of DMEM containing 1 × 105 293 T cells per well in triplicate in a 
96 well plate and allowed to incubate for 24 h. The luciferase activity 
was determined using the reporter lysis 5× buffer and luciferase as-
say reagent (LAR) system (Promega, Madison, WI). 40 mL of reporter 
lysis 5× buffer was added and allowed to incubate at room tempera-
ture for 20 min. Neutralization was defined as percent of virus only 
luciferase readout, which was then subtracted from 100%. We have 
defined neutralization as >90%, mild neutralization as 70–90% and 
nonneutralizing as <70%. 
2.5. Statistical analysis 
Statistical analyses were conducted using GraphPad Prism 7 soft-
ware. Non-parametric Mann-Whitney tests were used to determine 
statistical significance. P values ≤0.05 were considered statistically 
significant. 
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3. Results 
3.1. Maternal neutralizing antibodies against subgroups B, C, E 
and D adenoviruses 
Adenovirus seroprevalence has not been evaluated in Zambian ma-
ternal-infant pairs (MIPs); therefore, the impact of HIV-1 infection, 
and its treatment with ART, on (a) maternal nAb production, (b) trans-
fer of nAb to newborns, (c) the decay of maternal Ab in neonates, and 
(d) the development of infant de novo nAb responses, is incompletely 
understood. In order to estimate the seroprevalence of adenoviruses 
in Zambia, we tested 42 women in a pre- ART cohort and 25 women 
in a post-ART cohort for nAb against recombinant Ad7 (Group B), Ad5 
(Group C) and Ad4 (Group E) containing a GFPLuc reporter. Compar-
ison of responses in the two temporally distinct cohorts allowed for 
evaluation of the change in breadth and magnitude of Ad nAb coinci-
dent with ART implementation in the region. 
Other groups have defined neutralization with thresholds from 
50% up to 90% [25,32–35]. We conservatively defined neutraliza-
tion as ≥90% mean neutralization for n = 3 replicates. The number of 
women who neutralized Ad5 was not significantly different between 
the pre- and post-ART maternal cohorts, 93% and 88% respectively. 
The majority of women in the pre-ART cohort (52%) had neutralizing 
activity exceeding 90% against Ad4 and Ad7. However, only 28% of 
women in the post-ART cohort exhibited nAb responses against those 
types. (Fig. 1). 
Since species D adenoviruses were reported to be frequently iso-
lated from immunosuppressed subjects and those with keratoconjunc-
tivitis [36], and because this group was shown to have lower seroprev-
alence than Ads B, C, and E in other geographical regions, we tested 
for seroreactivity against four Group D Ads: Ad26, Ad28, Ad45 and 
Ad48 [26,27]. Given that these four Ads are members of the same Ad 
group, we anticipated levels of nAb to be similar in adults. Consistent 
with this concept, the majority of women in both the pre- and post-
ART cohort did neutralize Ad26, Ad28 and Ad45 (Fig. 1). The excep-
tion was Ad48 where <25% had detectable nAb (≥90%), irrespective 
of the cohort. 
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3.2. Transfer of maternal nAb and the impact of HIV infection in 
the pre-ART cohort 
To evaluate patterns of maternal pre- and perinatally nAb transfer 
to infants, the percent neutralization for each adenovirus was quan-
tified in sera collected from infants in 6-month intervals starting on 
the day of birth. The MIPs in the pre-ART cohort were recruited be-
tween 1998 and 2003, a time when Zambian women did not readily 
have access to ART treatment. Comparisons of the median nAb re-
sponses against each Ad subtype are shown in Fig. 2A and B. Median 
infant nAb responses were significantly lower than maternal against 
Ad4, Ad7, Ad26 and Ad28. In contrast, similar maternal and infant 
neutralizing responses were detected against Ad5 and Ad45. The me-
dian neutralization activity in infants against Ad5 and Ad45 was 99% 
and 99%, respectively. Because 4 of 28 maternal sera enhanced infec-
tion, median neutralizing activity against Ad48 was not significantly 
different between mothers and infants. These findings suggest that 
pre-existing immunity could lower the effectiveness of a vaccine vec-
tored with Ad5 or Ad45 if administered on the day of birth. 
Fig. 1. Neutralization profile of adult women in Zambia, Africa against Ad4, Ad5, 
Ad7, Ad26, Ad28 Ad45 and Ad48. 42 serum samples from the pre-ART cohort and 25 
samples from the post-ART cohort were evaluated for neutralizing activity against 
Ad4, Ad5, Ad7, Ad26, Ad28, Ad45, and Ad48 at a 1:30 sera dilution by luciferase-
based neutralization assay. Luciferase inhibition indicates viral neutralization by 
sera. Each sample was placed into one of three categories based on neutralization 
percentage compared to virus only samples: >90%, 90–70% or <70% which equates 
to highly neutralizing, mildly neutralizing, or non-neutralizing, respectively. 
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The pre-ART cohort was divided into two groups based on the HIV-1 
status of the mothers, while the infants, irrespective of their infection 
status, were correspondingly grouped with their mothers. No signif-
icant difference was seen in overall maternal nAb activity between 
HIV-1 infected and uninfected women (S1). Table 1 shows that mater-
nal HIV-1 infection significantly reduced transplacental transfer of Ad 
nAb only for subtypes Ad7 and Ad26. 
Fig. 2. Mother to Infant transfer of neutralizing antibodies in pre-ART cohort. A. 
Mother to infant nAb transfer in the pre-ART cohort. Neutralizing antibody trans-
fer was evaluated by a comparison of total medians of percent neutralization be-
tween mother and infant pairs on day of birth. Statistical significance was deter-
mined by nonparametric Mann-Whitney tests. B. Infant neutralization profile in 
the pre-ART cohort. Each infant sample was placed into one of three categories 
based on neutralization percentage compared to virus only samples: >90%, 90–
70% or <70% which equates to highly neutralizing, mildly neutralizing, or non-
neutralizing, respectively (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001). 
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3.3. Transfer of maternal neutralizing antibodies and impact of 
ART treatment in post-ART cohort 
In the post-ART cohort, infants received significantly less maternal 
nAb against all 7 tested adenoviruses compared to the median values 
from the pre-ART cohort (Fig. 3A and B). The highest median neu-
tralization in infants was against Ad5 at 93%, a value significantly 
lower than that from the pre-ART cohort (99%), but above the neu-
tralization threshold. Median infant neutralizing activity against all 
other adenoviruses was below 90%, and is therefore non-neutraliz-
ing or lacking in pre-existing immunity. 
To investigate whether or not ART treatment impacted the extent 
of nAb transfer to infants, the post-ART cohort was separated into 
ART-treated and -untreated mothers along with their corresponding 
infants. HIV-1 treated and untreated women showed no significance 
in overall maternal nAb activity (S1). Differential perinatal transfer 
was only evident for Ad5 nAb. This finding suggests that the overall 
decrease in Ad nAb in post-ART infants was not associated with ART-
mediated maternal immune reconstitution (Table 2). 
Table 1 Impact of maternal HIV infection on passive transfer of nAb on day of birth. 
For each MIP, the percent neutralization of the infant was divided by that of the 
cognate mother. The average of those ratios is reported for HIV-1 negative mothers 
(Column 2) versus positive (Column 3). Differences in the average of ratios based 
on HIV-1 status was statistically evaluated using non-parametric Mann-Whitney 
tests. A significant difference based on HIV-1 infection status was evident against 
Ad7 and Ad26 (*P ≤ 0.05). 
Adenovirus	 	HIV-		 HIV+	 	Significance		 P-Value	
Ad4  0.86  0.96  ns  0.230 
Ad5  1.00  1.00  ns  0.914 
Ad7  0.95  0.87  *  0.048 
Ad26  0.96  0.91  *  0.039 
Ad28  0.94  0.94  ns  0.907 
Ad45  1.00  0.99  ns  0.995 
Ad48  0.63  0.71  ns  0.658 
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Fig. 3. Mother to Infant transfer of neutralizing antibodies in post-ART cohort. A. 
Mother to infant nAb transfer in post-ART cohort. Neutralizing antibody transfer 
was evaluated by a comparison of total medians of neutralization between mother 
and infant pairs on day of enrollment (ENR) in the study. Infant ENR timepoint in-
cludes infants between 0 and 3 months of age. Statistical significance was deter-
mined by non-parametric Mann-Whitney tests. B. nAb profile of post-ART cohort 
infants. Each infant sample was placed into one of three categories based on neu-
tralization percentage compared to virus only samples: >90%, 90–70% or <70% 
which equates to highly neutralizing, mildly neutralizing, or non-neutralizing, re-
spectively (*P ≤0.05, ***P ≤ 0.001, ****P ≤ 0.0001). 
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3.4. Transfer of nAb between mothers and infants coincident 
with ART rollout 
To quantify the differentials in maternal nAb transfer to infants be-
tween the pre- and post-ART cohorts, we calculated the median ratios 
of infant to mother neutralization after conversion of those ratios as 
a percentage. We found that transferred nAb against all Ads, except-
ing Ad48, was significantly reduced in post-ART cohort infants (Fig. 
4). Ad48 also showed lower nAb, but the difference was not signifi-
cant. Since only modest variation in maternal Ad4 and Ad7 neutral-
ization was detected in response to HIV-1 infection or its treatment, 
this data suggests that neither variable altered the extent of nAb trans-
ferred to infants. 
3.5. Degradation of neutralizing antibodies over time 
In order to determine whether an optimal age for Ad-vectored in-
fant vaccination might exist, and which Ad subtype(s) platform would 
be most efficacious, we quantified infant Ad nAb over time. Starting 
form from initial levels near those of the maternal donor, infant nAb 
levels decreased starting at 6 months after birth (Fig. 5A and B). All 
Table 2 Effect of maternal ART treatment on transfer of nAb from mother to infant. 
For each MIP, the percent neutralization of the infant was divided by that of the 
cognate mother. The average of those ratios is reported for ART positive mothers 
(Column 2) versus negative (Column 3). Differences in the average of ratios based 
on treatment status was statistically evaluated using non-parametric Mann-Whit-
ney tests. A significant difference based on ART treatment status was evident only 
against Ad5 (*P ≤ 0.05). 
Adenovirus		 ART+		 ART-	 	Significance		 P-Value	
Ad4  0.47  0.45  ns  0.799 
Ad5  0.97  0.80  *  0.021 
Ad7  0.79  0.72  ns  0.903 
Ad26  0.88  0.89  ns  0.249 
Ad28  0.69  0.59  ns  0.217 
Ad45  0.65  0.63  ns  0.562 
Ad48  0.69  0.60  ns  0.411 
Privatt  et  al .  in  Vacc ine  37  (2019)     13
groups demonstrated a median neutralization below 70% at 12 months 
regardless of cohort or Ad. In both the pre and post-ART cohorts, the 
highest median neutralization was against Ad5 at 68.6% and 52.5% 
respectively. The lowest median nAb response was seen against Ad48 
(26.1%) in the pre-ART cohort and against Ad4 (8.5%) in the post-
ART cohort. 
In the pre-ART cohort, we were able to follow the nAb response 
against Ad4, Ad5, and Ad7 out to 36 months. The downward Ad nAb 
trend that starts at 6 months continued until 24 months of age, but 
began to trend upwards at 36 months presumably in response to de 
novo infections. This indicates that the infant population would be 
considered naïve and receptive to Ad vectored vaccines using any of 
the 7 adenoviruses. 
Fig. 4. Maternal to Infant nAb Transfer in pre-ART (1) and post-ART (2) cohorts. An 
analysis of the change in nAbs transferred to infants over time was done by com-
paring the fold change between the pre-ART and post-ART cohorts. Fold change 
was calculated by dividing the infant neutralization percentage by that of the cor-
responding mother neutralization percentage. The medians are shown and Mann-
Whitney tests were used to analyze statistical significance (*P ≤0.05, ***P ≤ 0.001, 
****P ≤ 0.0001). 
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Fig. 5. Neutralizing antibody decay over time in Zambian infants. Decay in neutral-
izing antibodies was evaluated at 0, 6, 12, 24 and 36 months for Ad4, Ad5, and Ad7 
in the pre-ART cohort (A). Only the 12 month time point was analyzed for the pre-
ART (A) for Ad26, Ad28, Ad45 and Ad48 and all Ads for the post-ART cohort (B) 
due to sampling limitations. Significant change in average neutralization was eval-
uated as a comparison to 0 months or enrollment (ENR) by Mann-Whitney analy-
sis (*P ≤0.05, ***P ≤ 0.001, ****P ≤ 0.0001). 
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4. Discussion 
The WHO reports nearly 90% of the world’s malaria infections, 
nearly 25% of TB cases, and 70% of HIV cases are located in Africa 
[2–4]. Many of the diseases that are prominent in the region either 
have no vaccine available or are of very low efficacy, high-cost or with 
cold-chain dependent options that need improvement. Children in SSA, 
and elsewhere, are often exposed to infectious diseases at a young 
age, which makes infant vaccination crucial for effective disease con-
trol and child well-being and development. Indeed, our lab and oth-
ers have demonstrated that seroconversion to Kaposi’s Sarcoma Her-
pesvirus (KSHV) occurs in sub-Saharan infants at levels near the adult 
prevalence by 4 years of age [37,38]. Using adenoviruses as a vaccine 
vector has been shown to elicit strong T and B cell responses to in-
serted transgenes and could also confer immunity to the Ad used as 
the backbone, thereby decreasing the burden of adenovirus associated 
diseases in young children. Adenoviruses are relatively easy to manip-
ulate and can be designed to be replication deficient where only the 
inserted transgene will be expressed in infected cells. Unlike many 
vaccine platforms, Ad based vaccines would not require cold storage. 
In combination with the fact that they can be grown to high titers in 
vitro at relatively low cost, this makes Adenovirus an ideal vector for 
vaccines that could realistically be implemented on a large scale in 
Africa [12,25]. 
While Adenoviruses have been studied for over 20 years for their 
use as a vaccine and gene therapy, it has been suggested that pre-ex-
posure can lead to decreased efficacy of the vector [14,19,20,39]. For 
this reason, we investigated the seroreactivity profile of Ad within 
Zambia to establish a targeted approach for future vaccine strategies 
in this region of SSA. Other groups previously investigated neutral-
ization against several of these Ads in sub-Saharan adults, but the re-
sults have been variable, and were not conducted longitudinally in 
children, the most likely recipients of vaccinations. In 2007, Abbink 
et al. reported seroreactivity to Ad5, Ad26, and Ad48 in SSA at 100%, 
21% and 3%, respectively [25]. However, in 2011, Barouch et al. re-
ported the South African adult Ad5, Ad26, and Ad48 seroprevalence 
to be 87.9–89.5%, 43.1–53.2%, and 13.3–24.6%, respectively [33]. 
Our results are in agreement with these reports for some Ad subtypes 
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whereas for others, the responses in our cohorts are distinct from than 
those cited above. For example, while the median nAb responses to Ad 
48 were also the lowest in both our cohorts, the magnitude of the re-
sponse was 3–20 fold higher than the studies cited above, at 64% and 
65.3% neutralization, respectively. In addition, low level neutraliza-
tion was readily detected in infants born to these mothers, whereas 
previous studies suggested that little Ad nAb was detected in young 
children [33]. Nevertheless, the discrepant results could be a func-
tion of changes or differences in circulating Ad genotypes/serotypes 
in the region over time, or differences in experimental methods used 
for quantifying neutralization. For example, we see a decrease in ma-
ternal nAb responses against Ad4 and Ad7 between the pre- and post-
ART cohorts which appears to correlate to a decrease in nAb transfer. 
This, however, does not explain the significant decrease in nAb trans-
fer in the post-ART cohort against Ad5, Ad26, Ad28 or Ad45. The ba-
sis of methodological differences is also unclear since other studies 
quantified neutralizing responses by serial dilution but were unable to 
detect nAb at a 1:2 dilution, whereas we readily detected ≥90% neu-
tralization at a 1:30 dilution of plasma. 
Two other studies have investigated Ad5 seroprevalence in both 
HIV-1 positive and negative adult populations. Both reported no sig-
nificant difference in Ad nAb between infected and uninfected pop-
ulations [40,41]. These data suggest two possibilities. The first, and 
less likely, is that development of Ad nAb responses are not impacted 
by alterations to the CD4 T cell compartment since T cell depletion in-
duced by HIV-1 infection did not diminish the neutralizing response. 
Alternatively, and perhaps more likely, the timing of infant de novo 
anti-adenoviral responses in our study suggests environmental expo-
sure to adenoviral infection early in life, long before initiation of sex-
ual activity. Thus, nAb responses had time to develop and mature im-
munological memory that likely is independent of CD4 T cell help in 
anamnestic responses. This second interpretation is supported by the 
lack of any statistically significant differential in Ad nAb responses 
in the mothers in our cohort as a result of ART treatment (i.e. CD4 T 
cell reconstitution). 
Our study is the first to longitudinally quantify the prevalence 
of nAb against a subset of Ads in infants starting at date-of-birth 
(DOB). This is a timepoint where nAbs are most likely derived prenatal 
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transfer of maternal nAb. In the pre-ART cohort infants, we found sig-
nificantly decreased nAb against Ad4, Ad7, Ad26, and Ad28, in com-
parison to the cognate mothers suggesting inefficient transfer or per-
haps insufficient titer in the mothers despite high % neutralization. 
In contrast, the infant DOB nAb levels to Ad5 and Ad45 approached 
adult levels, implying efficient transplacental transfer, whereas Ad48 
nAb in infants was below 90%. In the post-ART cohort, transfer of 
nAb against the investigated Ads was decreased. Of note, the median 
DOB percent neutralization of Ad5 was still high at 93%, in contradic-
tion to reports suggesting that infants lacked nAb against Ad5 [33]. 
A unique aspect of our study was the three-year follow-up of in-
fants that allowed us to quantify the decay of maternally transferred 
nAb and to identify the timing of potential de novo responses to Ad in-
fection. In both cohorts, median neutralization levels against all seven 
Ads was significantly lower by 12 months of age than at 0 months, and 
well below both the 90% and 70% threshold. Adenoviral infection and 
the resultant de novo humoral responses would explain the increases 
in infant nAb at 36 months seen against Ad4 and Ad5, this is consis-
tent with post-weaning exposure to fecal-oral pathogens through solid 
food and increased social interactions. This study is the first to ad-
dress the kinetics of nAb decay in infants where we potentially also 
identify exposure to the various Ads. Our findings implicate the exis-
tence of a window, between 12 and 24 months of age, that would sup-
port vaccination against regionally important pathogens without con-
cern for preexisting immunity. 
In this study, the changes in adult seroreactivity to seven different 
Adenoviruses as well as the decay of nAb in children were examined 
in order to establish a timeline for vaccination in Zambia. We found 
that none of the seven Ads should be used in adults without pre-exist-
ing immunity being a major consideration as most adults neutralized 
the virus. In contrast, children have a window for vaccination between 
12 and 24 months of age where maternally transferred antibodies de-
crease, and de novo infection has not yet occurred. All seven of the in-
vestigated Ads would work for this purpose since all showed low se-
roreactivity; but Ad4 and Ad7 are the most promising candidates as 
they had the lowest seroprevalence in the post-ART infants, and have 
already been tested for efficacy against adult Ad4 and Ad7 diseases in 
the United States military. 
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Appendix A. Supplementary material 
Supplemental Figure 1. Median percentage of neutralization in the 
mothers against all seven Ads was analyzed for significance based on HIV-1 
infection status (A) or ART treatment status (B). (** P ≤ 0.01)
Sup lemental Figure 1. Median percentage of neutralization i  the mothers against 
all seven Ads was analyzed for significance based on HIV-1 infection status (A)or 
ART treatment status (B). (** P ≤ 0.01)
Privatt  et  al .  in  Vacc ine  37  (2019)     19
References 
[1] Anonymous. HIV/AIDS; 2018. https://www.who.int/news-room/fact-sheets/
detail/hiv-aids.  
[2] Anonymous. Tuberculosis (TB); 2019. On World Health Organization. https://
afro.who.int/health-topics/tuberculosis-tb.  
[3] Anonymous. WHO|10 facts on malaria; 2016. On World Health Organization. 
https://www.who.int/features/factfiles/malaria/en/.  
[4] Anonymous. WHO|Data and statistics; 2018. On World Health Organization. 
https://www.who.int/hiv/data/en/.  
[5] Chen RF, Lee CY. Adenoviruses types, cell receptors and local innate cytokines 
in adenovirus infection. Int Rev Immunol 2014;33:45–53. 
[6] Alexander J, Ward S, Mendy J, Manayani DJ, Farness P, Avanzini JB, et al. 
Preclinical evaluation of a replication-competent recombinant adenovirus 
serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS ONE 
2012;7:e31177. 
[7] Stephenson KE, Keefer MC, Bunce CA, Frances D, Abbink P, Maxfield LF, 
Neubauer GH, Nkolola J, Peter L, Lane C, Park H, Verlinde C, Lombardo 
A, Yallop C, Havenga M, Fast P, Treanor J, Barouch DH. First-in-human 
randomized controlled trial of an oral, replicating adenovirus 26 vector 
vaccine for HIV-1. PLoS One 2018;13. 
[8] Barry M. Single-cycle adenovirus vectors in the current vaccine landscape. 
Exp Rev Vaccin 2018;17:163–73. 
[9] Weaver EA, Barry MA. Low seroprevalent species D adenovirus vectors as 
influenza vaccines. PLoS ONE 2013;8:e73313. 
[10] Gach JS, Gorlani A, Dotsey EY, Becerra JC, Anderson CT, Berzins B, et al. 
HIV-1- Specific antibody response and function after DNA prime and 
recombinant adenovirus 5 Boost HIV vaccine in HIV-Infected subjects. PLoS 
ONE 2016;11: e0160341. 
[11] Baden LR, Liu J, Li H, Johnson JA, Walsh SR, Kleinjan JA, et al. Induction 
of HIV- 1-specific mucosal immune responses following intramuscular 
recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect 
Dis 2015;211:518–28. 
[12] Bullard BL, Corder BN, Gorman MJ, Diamond MS, Weaver EA. Efficacy of a T 
cell-biased adenovirus vector as a Zika virus vaccine. Sci Rep 2018;8:18017. 
[13] Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, et al. 
Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors 
bypass immunity to Ad5 and protect nonhuman primates against ebolavirus 
challenge. J Virol 2011;85:4222–33. 
[14] Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, et al. 
A novel chimpanzee adenovirus vector with low human seroprevalence: 
improved systems for vector derivation and comparative immunogenicity. 
PLoS ONE 2012;7:e40385. 
[15] Zhu FC, Wurie AH, Hou LH, Liang Q, Li YH, Russell JB, et al. Safety and 
immunogenicity of a recombinant adenovirus type-5 vector-based Ebola 
vaccine in healthy adults in Sierra Leone: a single-centre, randomised, 
doubleblind, placebo-controlled, phase 2 trial. Lancet 2017;389:621–8. 
Privatt  et  al .  in  Vacc ine  37  (2019)      20
[16] Choudhry A, Mathena J, Albano JD, Yacovone M, Collins L. Safety evaluation 
of adenovirus type 4 and type 7 vaccine live, oral in military recruits. 
Vaccine 2016;34:4558–64. 
[17] Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: 
humoral, cellular, and innate response, what’s important? Hum Vaccin 
Immunother 2014;10:2875–84. 
[18] Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, et al. Prevalence 
of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult 
populations of the Gambia, South Africa, and the United States. Clin Diagn 
Lab Immunol 2004;11:351–7. 
[19] Alonso-Padilla J, Papp T, Kajan GL, Benko M, Havenga M, Lemckert A, et al. 
Development of novel adenoviral vectors to overcome challenges observed 
with HAdV-5-based constructs. Mol Ther 2016;24:6–16. 
[20] Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert 
PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener 
KM, Chodakewitz JA, Corey L, Robertson MN. Step Study Protocol TEfficacy 
assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a 
double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 
2008;372:1881–93. 
[21] Flasche S, Jit M, Rodriguez-Barraquer I, Coudeville L, Recker M, Koelle K, 
et al. The long-term safety, public health impact, and cost-effectiveness of 
routine vaccination with a recombinant, live-attenuated dengue vaccine 
(DENGVAXIA): a model comparison study. PLoS Med 2016;13:e1002181. 
[22] Halstead SB. Dengvaxia sensitizes seronegatives to vaccine enhanced disease 
regardless of age. Vaccine 2017;35:6355–8. 
[23] Pauly M, Hoppe E, Mugisha L, Petrzelkova K, Akoua-Koffi C, Couacy-Hymann 
E, et al. High prevalence and diversity of species D adenoviruses (HAdV-D) 
in human populations of four Sub-Saharan countries. Virol J 2014;11:25. 
[24] de Andrade Pereira B, Maduro Bouillet LE, Dorigo NA, Fraefel C, Bruna-
Romero O. Adenovirus specific pre-immunity induced by natural route of 
infection does not impair transduction by adenoviral vaccine vectors in 
mice. PLoS ONE 2015;10:e0145260. 
[25] Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, et al. 
Comparative seroprevalence and immunogenicity of six rare serotype 
recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 
2007;81:4654–63. 
[26] Duffy MR, Alonso-Padilla J, John L, Chandra N, Khan S, Ballmann MZ, et 
al. Generation and characterization of a novel candidate gene therapy and 
vaccination vector based on human species D adenovirus type 56. J Gen 
Virol 2018;99:135–47. 
[27] Farrow AL, Peng BJ, Gu L, Krendelchtchikov A, Matthews QL. A novel vaccine 
approach for Chagas disease using rare adenovirus serotype 48 vectors. 
Viruses 2016;8:78. 
[28] Lynch 3rd JP, Kajon AE. Adenovirus: epidemiology, global spread of novel 
serotypes, and advances in treatment and prevention. Semin Respir Crit 
Care Med 2016;37:586–602. 
Privatt  et  al .  in  Vacc ine  37  (2019)     21
[29] Scott MK, Chommanard C, Lu X, Appelgate D, Grenz L, Schneider E, et al. 
Human adenovirus associated with severe respiratory infection, Oregon, 
USA, 2013–2014. Emerg Infect Dis 2016;22:1044–51. 
[30] Mayindou G, Ngokana B, Sidibe A, Moundele V, Koukouikila-Koussounda 
F, Christevy Vouvoungui J, et al. Molecular epidemiology and surveillance 
of circulating rotavirus and adenovirus in Congolese children with 
gastroenteritis. J Med Virol 2016;88:596–605. 
[31] Weaver EA. Vaccines within vaccines: the use of adenovirus types 4 and 7 as 
influenza vaccine vectors. Hum Vaccin Immunother 2014;10:544–56. 
[32] Abbink P, Maxfield LF, Ng’ang’a D, Borducchi EN, Iampietro MJ, Bricault 
CA, et al. Construction and evaluation of novel rhesus monkey adenovirus 
vaccine vectors. J Virol 2015;89:1512–22. 
[33] Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al. 
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in 
pediatric and adult populations. Vaccine 2011;29:5203–9. 
[34] Yang WX, Zou XH, Jiang SY, Lu NN, Han M, Zhao JH, et al. Prevalence of 
serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) 
in children is associated with age and sanitary conditions. Vaccine 
2016;34:5579–86. 
[35] Zhang X, Wang J, Lu J, Li R, Zhao S. Correction to: Immunogenicity of 
adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety 
assessment in non-human primates. Virol J 2018;15:137. 
[36] Lion T. Adenovirus infections in immunocompetent and 
immunocompromised patients. Clin Microbiol Rev 2014;27:441–62. 
[37] Nalwoga A, Miley W, Labo N, Elliott A, Cose S, Whitby D, et al. Age of 
infection with Kaposi sarcoma-associated Herpesvirus and subsequent 
antibody values among children in Uganda. Pediatr Infect Dis J 
2018;37:e225–8. 
[38] Olp LN, Minhas V, Gondwe C, Poppe LK, Rogers AM, Kankasa C, et al. 
Longitudinal analysis of the humoral response to Kaposi’s sarcoma-
associated herpesvirus after primary infection in children. J Med Virol 
2016;88:1973–81. 
[39] Saxena M, Van TT, Baird FJ, Coloe PJ, Smooker PM. Pre-existing immunity 
against vaccine vectors–friend or foe? Microbiology 2013;159:1–11. 
[40] Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders G, Helmus N, 
et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports 
type 35 as a vaccine vector. Aids 2004;18:1213–6. 
[41] Sun C, Zhang Y, Feng L, Pan W, Zhang M, Hong Z, et al. Epidemiology of 
adenovirus type 5 neutralizing antibodies in healthy people and AIDS 
patients in Guangzhou, southern China. Vaccine 2011;29:3837–41.  
